Primary eosinophilic disorders: A concise review

Current Hematologic Malignancy Reports

Volumn 3, Issue 1, 2008, Pages 37-43

  Pardanani, Animesh ^b   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA2A INTERFERON; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYDROXYUREA; MEPOLIZUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; DISEASE CLASSIFICATION; EOSINOPHILIC LEUKEMIA; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; KARYOTYPE; PHENOTYPE; REVIEW; WORLD HEALTH ORGANIZATION;

EOSINOPHILIA; HUMANS; HYPEREOSINOPHILIC SYNDROME; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 41849136865     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0007-9     Document Type: Review

References (69)

1. Denburg JA, Telizyn S, Messner H, et al.: Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 1985, 66:312-318.
2. Boyce JA, Friend D, Matsumoto R, et al.: Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med 1995, 182:49-57.
3. Iwasaki H, Mizuno S, Mayfield R, et al.: Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 2005, 201:1891-1897.
4. McNagny K, Graf T: Making eosinophils through subtle shifts in transcription factor expression. J Exp Med 2002, 195:F43-F47.
5. Hirasawa R, Shimizu R, Takahashi S, et al.: Essential and instructive roles of GATA factors in eosinophil development. J Exp Med 2002, 195:1379-1386.
6. Yu C, Cantor AB, Yang H, et al.: Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002, 195:1387-1395.
7. Sanderson CJ: Interleukin-5, eosinophils, and disease. Blood 1992, 79:3101-3109.
8. Clutterbuck EJ, Hirst EM, Sanderson CJ: Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 1989, 73:1504-1512.
9. Collins PD, Marleau S, Griffiths-Johnson DA, et al.: Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995, 182:1169-1174.
10. Dent LA, Strath M, Mellor AL, Sanderson CJ: Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990, 172:1425-1431.
11. Basten A, Beeson PB: Mechanism of eosinophilia. II. Role of the lymphocyte. J Exp Med 1970, 131:1288-1305.
12. Nielsen K, Fogh L, Andersen S: Eosinophil response to migrating Ascaris suum larvae in normal and congenitally thymus-less mice. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1974, 82:919-920.
13. Hsu CK, Hsu SH, Whitney RA Jr, Hansen CT: Immunopathology of schistosomiasis in athymic mice. Nature 1976, 262:397-399.
14. Romagnani S: Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996, 80:225-235.
15. Brigden M, Graydon C: Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med 1997, 121:963-967.
16. Brito-Babapulle F: The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003, 121:203-223.
17. Tefferi A, Patnaik MM, Pardanani A: Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006, 133:468-492. A comprehensive and complete summary of secondary and primary eosinophilia.
18. Bain B, Pierre R, Imbert M, et al.: Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In World Health Organization Classification Of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, Vardiman JW. Lyon: International Agency for Research on Cancer Press; 2001:29-31.
19. Simon HU, Plotz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999, 341:1112-1120.
20. Butterfield JH: Diverse clinical outcomes of eosinophilic patients with T-cell receptor gene rearrangements: the emerging diagnostic importance of molecular genetics testing. Am J Hematol 2001, 68:81-86.
21. Chang HW, Leong KH, Koh DR, Lee SH: Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999, 93:1651-1657.
22. Bain BJ: Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004, 77:82-85.
23. Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007, In press. The new WHO classification system for myeloid neoplasms.
24. Malcovati L, La Starza R, Merante S, et al.: Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell. Haematologica 2004, 89:497-499.
25. Brown NJ, Stein RS: Idiopathic hypereosinophilic syndrome progressing to acute myelomonocytic leukemia with chloromas. South Med J 1989, 82:1303-1305.
26. Owen J, Scott JG: Transition of the hypereosinophilic syndrome to myelomonocytic leukemia. Can Med Assoc J 1979, 121:1489-1491.
27. Yoo TJ, Orman SV, Patil SR, et al.: Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet Cytogenet 1984, 11:389-384.
28. Needleman SW, Mane SM, Gutheil JC, et al.: Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol 1990, 4:149-155.
29. Klion AD, Bochner BS, Gleich GJ, et al.: Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006, 117:1292-1302.
30. Sato Y, Taniguchi R, Yamada T, et al.: Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med 2000, 39:350.
31. Pitini V, Arrigo C, Azzarello D, et al.: Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003, 102:3456-3457; author reply 3457.
32. Butterfield JH, Gleich GJ: Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994, 121:648-653.
33. Baratta L, Afeltra A, Delfino M, et al.: Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy - case report and literature review. Angiology 2002, 53:465-470.
34. Yoon TY, Ahn GB, Chang SH: Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol 2000, 27:110-115.
35. Ceretelli S, Capochiani E, Petrini M: Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 1998, 77:161-164.
36. Parrillo JE, Fauci AS, Wolff SM: Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978, 89:167-172.
37. Pardanani A, Brockman SR, Paternoster SF, et al.: FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004, 104:3038-3045. Clarification of the phenotype associated with FIP1L1-PDGFRA.
38. Sefcick A, Sowter D, DasGupta E, et al.: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004, 124:558-559.
39. Pitini V, Teti D, Arrigo C, Righi M: Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004, 127:477.
40. Alinari L, Lapalombella R, Andritsos L, et al.: Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007, 26:3644-3653.
41. Elsner J, Hochstetter R, Spiekermann K, Kapp A: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996, 88:4684-4693.
42. Au WY, Leung AY, Tse EW, et al.: High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res 2007, In press.
43. Peleg AY, Husain S, Kwak EJ, et al.: Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007, 44:204-212.
44. Koury MJ, Newman JH, Murray JJ: Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med 2003, 115:587-589.
45. Plotz SG, Simon HU, Darsow U, et al.: Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003, 349:2334-2339.
46. Klion AD, Law MA, Noel P, et al.: Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004, 103:2939-2941.
47. Kim YJ, Prussin C, Martin B, et al.: Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004, 114:1449-1455.
48. Jabbour E, Verstovsek S, Giles F, et al.: 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005, 104:541-546.
49. Cools J, DeAngelo DJ, Gotlib J, et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
50. Tefferi A, Gilliland DG: Oncogenes in myeloproliferative disorders. Cell Cycle 2007, 6:550-566.
51. Pardanani A, Ketterling RP, Li CY, et al.: FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006, 30:965-970. Prevalence of FIP1L1-PDGFRA in routine clinical practice.
52. Jovanovic JV, Score J, Waghorn K, et al.: Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635-4640. The use of molecular assays in accurate disease diagnosis and monitoring of treatment in patients with FIP1L1-PDGFRA-associated eosinophilic neoplasm.
53. von Bubnoff N, Sandherr M, Schlimok G, et al.: Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005, 19:286-287.
54. Ohnishi H, Kandabashi K, Maeda Y, et al.: Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006, 134:547-549.
55. Cools J, Stover EH, Boulton CL, et al.: PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDG-FRalpha-induced myeloproliferative disease. Cancer Cell 2003, 3:459-469.
56. Lierman E, Folens C, Stover EH, et al.: Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108:1374-1376.
57. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
58. Levine RL, Wadleigh M, Sternberg DW, et al.: KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 2005, 19:27-30.
59. Vizmanos JL, Novo FJ, Roman JP, et al.: NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 2004, 64:2673-2676.
60. Wilkinson K, Velloso ER, Lopes LF, et al.: Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003, 102:4187-4190.
61. Apperley JF, Gardembas M, Melo JV, et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
62. Grand FH, Burgstaller S, Kuhr T, et al.: p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004, 64:7216-7219.
63. Walz C, Metzgeroth G, Haferlach C, et al.: Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 2007, 92:163-169.
64. Macdonald D, Reiter A, Cross NC: The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002, 107:101-107.
65. Raghavachar A, Fleischer S, Frickhofen N, et al.: T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987, 139:3753-3758.
66. Cogan E, Schandene L, Crusiaux A, et al.: Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994, 330:535-538.
67. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al.: Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005, 19:792-798.
68. Vaklavas C, Tefferi A, Butterfield J, et al.: "Idiopathic" eosinophilia with an occult T-cell clone: prevalence and clinical course. Leuk Res 2007, 31:691-694.
69. Roufosse F, Cogan E, Goldman M: Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004, 59:673-689.